[Psychiatric intensive therapy after acute alkaloid withdrawal syndrome].
Two groups of patients (nine patients each) were treated for acute alcaloid-withdrawal-syndromes. One group was given peroral neuroleptic medication, the other was treated by neuroleptic cocktail administered via vena subclavia catheter. By statistic comparison of the two methods the superiority of the latter could be shown in that duration of withdrawal, the syndrome itself and hallucinatory transitional psychoses could be drastically reduced. A suitable prescription and dosages of the neuroleptic cocktail are presented. The results are compared to the ones in current literature.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002404:Catheterization; D002749:Chlorprothixene / Q000627:therapeutic use; D004878:Ergotamine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use; D013350:Subclavian Vein; D013375:Substance Withdrawal Syndrome / Q000628:therapy*
D014150:Antipsychotic Agents; D011720:Pyrazoles; D002749:Chlorprothixene; D006220:Haloperidol; D004878:Ergotamine
Zur psychiatrischen Intensivtherapie des akuten Alkaloidentzugssyndroms.